Research of FUZHUAN Tea&#x02019;s Therapy for Hyperlipidemia by High-Throughput Screening

FU Dong-he; LIU Zhong-hua; HUANG Jianan; GONG Yu-shun; CHEN Jin-hua

doi:10.13305/j.cnki.jts.2006.03.011

PDF(340 KB)

Journal of Tea Science ›› 2006, Vol. 26 ›› Issue (3) : 209-214. DOI: 10.13305/j.cnki.jts.2006.03.011

Research of FUZHUAN Tea’s Therapy for Hyperlipidemia by High-Throughput Screening

FU Dong-he, LIU Zhong-hua^*, HUANG Jianan, GONG Yu-shun, CHEN Jin-hua

Author information +

History +

Abstract

Searching high effective and natural medicines for therapy for hyperlipidemia is one of the focus of research. High-Throughput Screening is a kind of new technique of medicine screening. The water extractions of FUZHUAN Tea were extracted by chloroform, ethyl acetate, 1-butanol separately. The samples were used to test their function of adjusting fat metabolism of FUZHUAN Tea by the models of PPARα, PPARγ, PPARδ, LXR, FXR and 3T3-L1 of High-Throughput Screening. The results showed that FUZHUAN Tea could activate PPARγ, PPARδ and restrain FXR. Its effect to PPRAα and 3T3-L1 was not obvious. FUZHUAN Tea was effective in therapy for hyperlipidemia. The active components need to be separated later.

Key words

3T3-L1 / Fuzhuan Tea / FXR / high-Throughput Screening / LXR / PPARα / PPARγ / PPARδ

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

FU Dong-he, LIU Zhong-hua, HUANG Jianan, GONG Yu-shun, CHEN Jin-hua. Research of FUZHUAN Tea’s Therapy for Hyperlipidemia by High-Throughput Screening[J]. Journal of Tea Science. 2006, 26(3): 209-214 https://doi.org/10.13305/j.cnki.jts.2006.03.011

References

[1] 马君. 肥胖症研究新进展[J]. 国外医学护理学分册, 2000, 19(7): 310.
[2] 汪东风, 谢晓凤, 王银龙. 茶叶多糖及其药理作用研究进展[J]. 天然产物研究与开发, 1996, 2(1): 63~68.
[3] 刘波静. 茶多酚对动物血清血脂和载脂蛋白水平的影响和抗氧化作用[J]. 茶叶科学, 2000, 20(1): 67~70.
[4] 杜冠华. 高通量药物筛选在新药研究中的应用[J]. 基础医学与临床, 2001, 21(4): 289~293.
[5] 杜冠华. 高通量药物筛选与中药现代化研究[J]. 中成药, 1999, 21(5): 268~270.
[6] 季莉莉. PPAR-δ与疾病(国外医学卫生学分册)[J]. 2005, 32(4): 214~217.
[7] 孙曙光. PPARγ与1型糖尿病[J]. 国外医学内分泌学分册, 2005, 25(2): 96~98.
[8] Makishima M, Okamoto A, Repa J, et al. Identification of a nuclear receptor for bile acid[J]. Science, 1999(284): 1362~1365.
[9] 李烁, 张志文, 管又飞. 胆汁酸受体FXR 的研究进展[J]. 生理科学进展, 2003, 34(4): 314~318.
[10] 吴静, 张志文, 管又飞. LXRs 在脂质代谢中的作用[J]. 生理科学进展, 2004, 35(1): 69~72.
[11] 张盛, 刘仲华, 黄建安, 等. 吸附树脂法制备高纯儿茶素的研究[J]. 茶叶科学, 2002, 22(2): 125~130.
[12] 商业部茶叶畜产局和杭州茶叶加工研究所. 茶叶品质理化分析第1版[M]. 上海: 上海科学技术出版社, 1989.
[13] 王坤波, 刘仲华, 黄建安. 儿茶素体外氧化制备茶黄素的研究[J]. 茶叶科学, 2004, 24(1): 53~59.
[14] Zhang Y, Repa JJ, Gauthier K, et al Regulation of lipoprotcin lipase by the oxysterol receptors, LXR alpha and LXR beta[J]. Biol.Chem, 2001, 276(46): 43018~43024.
[15] 张嘉杰, 徐伟, 雷林生, 等. 类法尼醇X受体的功能及其配体的研究进展[J]. 国外医学·生理、病理科学与临床分册, 2003(4): 403~406.
[16] Urizar NL, Liveryman AB, Dodd’s DT, et al. A natural product that lowers cholesterol as antagonist ligand for FXR[J]. Science, 2002, 296: 1703~1706.
[17] 应之和. 茶多酚对高脂血症患者的降脂作用观察[J]. 浙江实用医学, .2002, 7(4): 223, 228.
[18] 张红锋, 徐曼艳. 茶多酚对高脂鹌鹑的血脂和肝细胞贮脂水平的影响[J]. 中国药学杂志, 2002, 37(5): 342~346.
[19] 宛晓春. 茶叶生物化学(第三版)[M]. 北京:中国农业出版社, 2003: 338.